AR011133A1 - MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA. - Google Patents

MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.

Info

Publication number
AR011133A1
AR011133A1 ARP980100613A ARP980100613A AR011133A1 AR 011133 A1 AR011133 A1 AR 011133A1 AR P980100613 A ARP980100613 A AR P980100613A AR P980100613 A ARP980100613 A AR P980100613A AR 011133 A1 AR011133 A1 AR 011133A1
Authority
AR
Argentina
Prior art keywords
association
manufacture
controlled release
procedure
polychimotherapy
Prior art date
Application number
ARP980100613A
Other languages
English (en)
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of AR011133A1 publication Critical patent/AR011133A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a una nueva formulacion de cisplatina, para administracion oral, en forma de microgránulos de liberacion controlada, así como su procedimientode preparacion por montaje en medio acuoso. La misma se refiere también a una preparacionfarma céutica que contiene los microgránulos de cisplatina deliberacion controlada y un agente anticanceroso como producto de combinacion para una utilizacion simultánea, separada o extendida en el tiempo en terapiaanticancerosa, así como lautilizacion de dichos microgránulos para fabricar un medicamento para administrar por vía oral destinado a ser utilizado enpoliquimioterapia o en asociacion con una radioterapia.
ARP980100613A 1997-02-11 1998-02-11 MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA. AR011133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9701545A FR2759293B1 (fr) 1997-02-11 1997-02-11 Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie

Publications (1)

Publication Number Publication Date
AR011133A1 true AR011133A1 (es) 2000-08-02

Family

ID=9503556

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100613A AR011133A1 (es) 1997-02-11 1998-02-11 MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.

Country Status (24)

Country Link
US (2) US6458389B1 (es)
EP (1) EP0971702B1 (es)
JP (1) JP4549445B2 (es)
KR (1) KR100471672B1 (es)
AR (1) AR011133A1 (es)
AT (1) ATE255409T1 (es)
BG (1) BG64247B1 (es)
BR (1) BR9807319A (es)
CA (1) CA2282082C (es)
DE (1) DE69820239T2 (es)
DK (1) DK0971702T3 (es)
EA (1) EA001760B1 (es)
ES (1) ES2210726T3 (es)
FR (1) FR2759293B1 (es)
HU (1) HU225425B1 (es)
IL (1) IL131326A (es)
IN (1) IN187998B (es)
NO (1) NO323230B1 (es)
NZ (1) NZ337216A (es)
PL (1) PL191631B1 (es)
PT (1) PT971702E (es)
TW (1) TW561055B (es)
WO (1) WO1998034599A1 (es)
ZA (1) ZA981123B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096304A1 (en) * 1998-09-08 2005-05-05 David White Method of treating cancer using dithiocarbamate derivatives
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
BR0010649A (pt) * 1999-05-17 2002-02-19 D B F Grãnulos que contêm pelo menos uma substância vegetal e processo de preparação dos mesmos
JP5171038B2 (ja) * 2003-10-10 2013-03-27 エティファルム イチョウ・エキスを含む放出持続性の微小顆粒およびそのような顆粒の製造方法
FR2861990B1 (fr) 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
AR052142A1 (es) * 2004-11-18 2007-03-07 Bristol Myers Squibb Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
JPWO2006062072A1 (ja) * 2004-12-10 2008-08-07 テムリック株式会社 転移癌治療剤および癌転移抑制剤
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
JP5204846B2 (ja) * 2007-09-21 2013-06-05 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング エタノールの影響に対して耐性を有する非オピオイド薬のｐＨ依存性制御放出医薬組成物
CN101801357B (zh) * 2007-09-21 2013-08-07 赢创罗姆有限公司 耐受乙醇的影响的pH依赖性受控释放的药物组合物
MX2010007577A (es) * 2008-01-10 2010-08-04 Evonik Roehm Gmbh Preparacion nutriceutica o farmaceutica revestida con una sustancia activa mejorada liberada en el colon.
BRPI0821985A2 (pt) * 2008-01-10 2015-06-23 Evonik Roehm Gmbh Preparacao farmacêutica ou nutracêutica revestida tendo liberação de substância ativa controlada
DK177529B1 (en) * 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
CA2688202C (en) * 2009-12-11 2012-11-13 Bj Services Company Viscoelastic fluids containing hydroxyethyl cellulose
EP2371356B1 (en) * 2010-03-12 2012-12-19 Phoeme GmbH Multi-particle pharmaceutical formulation for colon absorption
US8070047B1 (en) * 2010-12-02 2011-12-06 Rohm And Haas Electronic Materials Llc Flux composition and method of soldering
JP2015530387A (ja) 2012-09-04 2015-10-15 エライゾン ファーマシューティカルズ， エルエルシー 脂質複合体化シスプラチンによる肺癌の再発防止
CA2959414C (en) 2014-09-05 2023-03-14 Symbiomix Therapeutics, Llc Secnidazole for use in the treatment of bacterial vaginosis
US10238688B2 (en) * 2015-04-24 2019-03-26 Genedia Biotech Co., Ltd. Combination therapies for bladder cancer
WO2016196653A1 (en) * 2015-06-01 2016-12-08 Symbiomix Therapeutics, Llc Novel nitroimidazole formulations and uses thereof
US11433146B2 (en) 2015-06-12 2022-09-06 Vaxart, Inc. Formulations for small intestinal delivery of RSV and norovirus antigens
CN112236146A (zh) * 2018-04-24 2021-01-15 盐野义制药株式会社 稳定性优良的固体制剂
MX2020011130A (es) * 2018-04-24 2022-09-09 Shionogi & Co Forma de dosificacion solida que tiene excelente estabilidad.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059817B1 (fr) * 1981-03-11 1985-10-09 Mirko Beljanski Serpentine; alstonine et sempervirine, médicaments inhibant spécifiquement les cellules cancéreuses et tumorales
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
DE3523454A1 (de) * 1985-07-01 1987-01-08 Eberhard Prof Dr Nuernberg Formkoerper
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH05294839A (ja) * 1992-04-20 1993-11-09 Biomaterial Universe Kk シスプラチン含有生体内分解吸収性高分子の微小球お よびその製造法
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
JPH0789849A (ja) * 1993-09-20 1995-04-04 Fujisawa Pharmaceut Co Ltd 徐放性製剤
JPH0859460A (ja) * 1994-08-22 1996-03-05 Tanaka Kikinzoku Kogyo Kk 抗ガン剤内包キトサンミクロスフェア及びその製造法
US5637319A (en) * 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
DK0929293T3 (da) * 1996-08-23 2004-02-02 Sequus Pharm Inc Liposomer indeholdende en cisplatinforbindelse

Also Published As

Publication number Publication date
JP2001512433A (ja) 2001-08-21
HU225425B1 (en) 2006-11-28
AU6626798A (en) 1998-08-26
DE69820239D1 (de) 2004-01-15
PL335107A1 (en) 2000-04-10
ZA981123B (en) 1998-08-20
EP0971702A1 (fr) 2000-01-19
KR20000070997A (ko) 2000-11-25
DK0971702T3 (da) 2004-04-13
NZ337216A (en) 2000-09-29
ES2210726T3 (es) 2004-07-01
FR2759293B1 (fr) 1999-04-30
DE69820239T2 (de) 2004-10-07
AU744001B2 (en) 2002-02-14
EA001760B1 (ru) 2001-08-27
HUP0001719A3 (en) 2005-11-28
NO993881D0 (no) 1999-08-11
NO993881L (no) 1999-09-29
TW561055B (en) 2003-11-11
BG64247B1 (bg) 2004-07-30
KR100471672B1 (ko) 2005-03-07
IL131326A (en) 2005-03-20
BR9807319A (pt) 2000-04-18
FR2759293A1 (fr) 1998-08-14
EP0971702B1 (fr) 2003-12-03
US6458389B1 (en) 2002-10-01
JP4549445B2 (ja) 2010-09-22
US20030017210A1 (en) 2003-01-23
IL131326A0 (en) 2001-01-28
PT971702E (pt) 2004-04-30
CA2282082A1 (fr) 1998-08-13
BG103647A (en) 2000-03-31
WO1998034599A1 (fr) 1998-08-13
NO323230B1 (no) 2007-02-05
ATE255409T1 (de) 2003-12-15
HUP0001719A2 (hu) 2000-11-28
IN187998B (es) 2002-08-03
PL191631B1 (pl) 2006-06-30
EA199900734A1 (ru) 2000-04-24
CA2282082C (fr) 2005-10-18

Similar Documents

Publication Publication Date Title
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
KR102373297B1 (ko) 피부 질병의 치료를 위한 조성물, 방법 및 시스템
CA2402169A1 (en) Formulation and method for treating neoplasms by inhalation
BR0013948A (pt) Prodroga, composição farmacêutica, e, método de tratamento de um paciente mamìfero
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
GB0007419D0 (en) Composition
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
BR0007974A (pt) Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
AR066313A2 (es) Una formulacion de liberacion controlada de galantamina, una forma farmaceutica de dosificacion, un proceso para la preparacion de dicha formulacion, y el uso de dicha formulacion para la manufactura de un medicamento
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
WO1995030423A3 (en) Cancer treatment and metastasis prevention
Oguchi et al. Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis
AR033671A1 (es) Composicion farmaceutica acuosa del tipo de gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
JP7280870B2 (ja) 皮膚障害の処置
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
UY25192A1 (es) Formulación medicamentosa con liberación controlada de sustancia activa
DE69215999D1 (de) Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
AR036877A1 (es) Formulacion farmaceutica
ES2303811T1 (es) Uso de anastrozol para el tratamiento post-menopausico de una mujer que tiene cancer de mama temprano.
HN2001000038A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
AR029415A1 (es) Pirroles sustituidos, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos

Legal Events

Date Code Title Description
FG Grant, registration